A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis

Vaccine

Volumn 28, Issue 46, 2010, Pages 7427-7435

  Llanos Cuentas, Alejandro ^a   Calderón, Wessmark ^a   Cruz, María ^a   Ashman, Jill A ^b   Alves, Fabiana P ^b,c   Coler, Rhea N ^b   Bogatzki, Lisa Y ^b,d   Bertholet, Sylvie ^b   Laughlin, Elsa M ^b,e   Kahn, Stuart J ^b,f   Beckmann, Anna Marie ^b   Cowgill, Karen D ^b   Reed, Steven G ^b   Piazza, Franco M ^b  

^a INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c Drugs for Neglected Diseases initiative DNDi   (Brazil)

^d Trubion Pharmaceuticals   (United States)

^e NOVO NORDISK INC   (United States)

^f SYNTRIX BIOSYSTEMS INC   (United States)

Author keywords

Adjuvants; Immunologic; Leishmaniasis; Leishmaniasis vaccines; Mucosal

Indexed keywords

AMINOTRANSFERASE; CD4 ANTIGEN; CD45RO ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; INTERLEUKIN 5; LEISHMANIA VACCINE; PLACEBO; STIBOGLUCONATE SODIUM;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVALUATION; FATIGUE; FEMALE; FEVER; HEADACHE; HEPATITIS; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MEMORY CELL; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STAINING; VACCINATION;

ADULT; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; CYTOKINES; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; LEISHMANIASIS VACCINES; LEISHMANIASIS, MUCOCUTANEOUS; MALE; MIDDLE AGED; TH1 CELLS; YOUNG ADULT;

EID: 77958184848     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.092     Document Type: Article

References (13)

1. Magill A.J. Leishmaniasis. Hunter's tropical medicine and emerging tropical diseases 2000, 665-687. WB Saunders Company, Philadelphia. G.T. Strickland (Ed.).
2. Velez I.D., Gilchrist K., Martinez S., Ramirez-Pineda J.R., Ashman J.A., Alves F.P., et al. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 2010, 28:329-337.
3. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002, 70(August (8)):4215-4225.
4. Llanos-Cuentas A., Echevarria J., Cruz M., La Rosa A., Campos P., Campos M., et al. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin Infect Dis 1997, 25(September (3)):677-684.
5. ICSSC Monitoring and reporting adverse events: Appendix VII www resource links 2003, [updated February 6, cited 2009 April 6], Available from: http://www.icssc.org/Documents/Resources/AEManual2003AppendicesFebruary_06_2003%20final.pdf.
6. Newson R. Parameters behind " nonparametric" statistics: Kendall's tau, Somers' D and median differences. Stata J 2002, 2(1):45-64.
7. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998, 66(July (7)):3279-3289.
8. Webb J.R., Kaufmann D., Campos-Neto A., Reed S.G. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J Immunol 1996, 157(December (11)):5034-5041.
9. De Luca P.M., Mayrink W., Santiago M.A., Nogueira R., Conceicao-Silva F., Melo G., et al. Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test. Trans R Soc Trop Med Hyg 2003, 97(November-December (6)):709-712.
10. Nascimento M.D., Alcantara-Neves N.M., Muniz M.E., Nunes S.F., Paranhos M., de Carvalho L.C. Induction and modulation of the immune response to Leishmania by Montenegro's skin test. Trans R Soc Trop Med Hyg 1993, 87(January-February (1)):91-93.
11. Satti I., el Hassan A., Khalil el T.A., Akuffo H. The effect of repeated leishmanin skin testing on the immune responses to Leishmania antigen in healthy volunteers. Trans R Soc Trop Med Hyg 2002, 96(September-October (5)):565-567.
12. Maurer-Cecchini A., Decuypere S., Chappuis F., Alexandrenne C., De Doncker S., Boelaert M., et al. Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials. Infect Immun 2009, 77(May (5)):2022-2029.
13. Amato V.S., Tuon F.F., Siqueira A.M., Nicodemo A.C., Neto V.A. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg 2007, 77(August (2)):266-274.